Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poziotinib in EGFR or HER2 Mutant Advanced Solid Tumors
NCT03066206Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2017
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of poziotinib in non-small cell lung cancer (NSCLC), solid tumor, sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2017; status: terminated.
02
Drugs
poziotinib
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT03066206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03066206.